Aggressive progression to EGFR tyrosine kinase inhibitors in advanced NSCLC patients: concomitant mutations, prognostic indicator and subsequent management

BACKGROUND: EGFR tyrosine kinase (TKIs) are recommend as the first-line treatment for non-small cell lung cancer (NSCLC) patients with EGFR mutation. However, some patients experience aggressive progression with a progression-free survival (PFS) less than 6 months on the first-line EGFR TKI therapy....

Descripción completa

Detalles Bibliográficos
Autores principales: Wen, Ruishan, Chen, Ying, Long, Jinyu, Huang, Xiulian, Guo, Yuxin, Lin, Baoquan, Yu, Zongyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374808/
https://www.ncbi.nlm.nih.gov/pubmed/37074454
http://dx.doi.org/10.1007/s00432-023-04757-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374808/
https://www.ncbi.nlm.nih.gov/pubmed/37074454
http://dx.doi.org/10.1007/s00432-023-04757-4

Ejemplares similares